- Home
- EPRX vs ECOR Comparison
EPRX vs ECOR Comparison
Compare EPRX & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPRX
- ECOR
- Stock Information
- Founded
- EPRX 2011
- ECOR 2005
- Country
- EPRX Canada
- ECOR United States
- Employees
- EPRX N/A
- ECOR N/A
- Industry
- EPRX
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- EPRX
- ECOR Health Care
- Exchange
- EPRX NYSE
- ECOR Nasdaq
- Market Cap
- EPRX 109.7M
- ECOR 110.4M
- IPO Year
- EPRX N/A
- ECOR 2018
- Fundamental
- Price
- EPRX $3.65
- ECOR $17.67
- Analyst Decision
- EPRX Strong Buy
- ECOR Strong Buy
- Analyst Count
- EPRX 1
- ECOR 1
- Target Price
- EPRX $9.00
- ECOR $25.00
- AVG Volume (30 Days)
- EPRX 15.8K
- ECOR 104.7K
- Earning Date
- EPRX 03-04-2025
- ECOR 03-12-2025
- Dividend Yield
- EPRX N/A
- ECOR N/A
- EPS Growth
- EPRX N/A
- ECOR N/A
- EPS
- EPRX N/A
- ECOR N/A
- Revenue
- EPRX N/A
- ECOR $23,327,000.00
- Revenue This Year
- EPRX N/A
- ECOR $59.81
- Revenue Next Year
- EPRX N/A
- ECOR $38.49
- P/E Ratio
- EPRX N/A
- ECOR N/A
- Revenue Growth
- EPRX N/A
- ECOR 74.10
- 52 Week Low
- EPRX $2.20
- ECOR $5.32
- 52 Week High
- EPRX $4.08
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- EPRX N/A
- ECOR 55.62
- Support Level
- EPRX N/A
- ECOR $15.83
- Resistance Level
- EPRX N/A
- ECOR $19.43
- Average True Range (ATR)
- EPRX 0.00
- ECOR 1.19
- MACD
- EPRX 0.00
- ECOR 0.17
- Stochastic Oscillator
- EPRX 0.00
- ECOR 58.06
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.